Anacor Pharmaceuticals, Inc. (ANAC)

99.20
NASDAQ
Prev Close 99.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
New Lifetime High For Anacor Pharmaceuticals (ANAC)

New Lifetime High For Anacor Pharmaceuticals (ANAC)

Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a new lifetime high candidate

Short Interest Moves 26.7% Higher For ANAC

Short Interest Moves 26.7% Higher For ANAC

The most recent short interest data has been released by the NASDAQ for the 07/31/2014 settlement date, which shows a 1,412,779 share increase in total short interest for Anacor Pharmaceuticals Inc , to 6,695,631, an increase of 26.74% since 07/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Anacor Pharmaceuticals Reports Second Quarter 2014 Financial Results

Anacor Pharmaceuticals Reports Second Quarter 2014 Financial Results

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended June 30, 2014.

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals To Present At Upcoming Investor Conferences

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Geoff Parker, the company’s Chief Financial Officer, will provide a company overview at the following investor conferences: ...

Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces Second Quarter 2014 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) will release its financial results for the second quarter ended June 30, 2014, on Thursday, August 7, 2014 at approximately 4:00 p.

3 Stocks Rising on Big Volume

3 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Anacor Pharmaceuticals And Sandoz Enter Into An Agreement For The Commercialization Of KERYDIN In The United States

Anacor Pharmaceuticals And Sandoz Enter Into An Agreement For The Commercialization Of KERYDIN In The United States

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc.

3 Big-Volume Stocks in Breakout Territory

3 Big-Volume Stocks in Breakout Territory

These stocks rising on unusual volume are within range of triggering breakout trades.

FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% For The Treatment Of Onychomycosis Of The Toenails

FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% For The Treatment Of Onychomycosis Of The Toenails

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.

Interesting ANAC Put And Call Options For February 2015

Interesting ANAC Put And Call Options For February 2015

Investors in Anacor Pharmaceuticals Inc saw new options begin trading this week, for the February 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Anacor Pharmaceuticals Appoints Keith R. Leonard, Jr. To Board Of Directors

Anacor Pharmaceuticals Appoints Keith R. Leonard, Jr. To Board Of Directors

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has unanimously appointed Keith R.

Anacor Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference

Anacor Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at the Jefferies 2014 Global Healthcare Conference on ...

Anacor Pharmaceuticals To Present At The UBS Global Health Care Conference

Anacor Pharmaceuticals To Present At The UBS Global Health Care Conference

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at the UBS Global Health Care Conference on Monday, ...

Short Interest In Anacor Pharmaceuticals Increases 13%

Short Interest In Anacor Pharmaceuticals Increases 13%

The most recent short interest data has been released by the NASDAQ for the 04/30/2014 settlement date, which shows a 368,069 share increase in total short interest for Anacor Pharmaceuticals Inc , to 3,196,242, an increase of 13.01% since 04/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Anacor Pharmaceuticals (ANAC) Shares Cross Below 200 DMA

Anacor Pharmaceuticals (ANAC) Shares Cross Below 200 DMA

In trading on Friday, shares of Anacor Pharmaceuticals Inc crossed below their 200 day moving average of $14.85, changing hands as low as $14.45 per share. Anacor Pharmaceuticals Inc shares are currently trading down about 2.9% on the day.

Anacor Pharmaceuticals Inc Stock Downgraded (ANAC)

Anacor Pharmaceuticals Inc Stock Downgraded (ANAC)

Anacor Pharmaceuticals (Nasdaq:ANAC) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: BEE, CHK, DVN, GTY, LPI, RDN, STRA, UDR Downgrades: ANAC, AYR, BSFT, CLMT, CTHR, CTRP, DEG, KT, LOGI, PHH, PLD, QRE, QUAD, SNSS Initiations: BSMX, MRIN Read on to get TheStreet Quant Ratings' detailed report:

Anacor Pharmaceuticals Reports First Quarter 2014 Financial Results

Anacor Pharmaceuticals Reports First Quarter 2014 Financial Results

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the first quarter ended March 31, 2014.

Anacor Pharmaceuticals Announces First Quarter 2014 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces First Quarter 2014 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the first quarter ended March 31, 2014, on Wednesday, May 7, 2014 at approximately 4:00 p.

Anacor Pharmaceuticals To Present At Deutsche Bank’s 39th Annual Health Care Conference

Anacor Pharmaceuticals To Present At Deutsche Bank’s 39th Annual Health Care Conference

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company’s President and Chief Executive Officer, will provide a company overview at Deutsche Bank’s 39th Annual Health Care...

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

Anacor Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of AN2728 In Mild-to-Moderate Atopic Dermatitis

Anacor Pharmaceuticals Announces First Patient Enrolled In Phase 3 Trial Of AN2728 In Mild-to-Moderate Atopic Dermatitis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of...

Interesting ANAC Put And Call Options For November 22nd

Interesting ANAC Put And Call Options For November 22nd

Investors in Anacor Pharmaceuticals Inc saw new options begin trading this week, for the November 22nd expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Insider Trading Alert - ANAC, N And PRAA Traded By Insiders

Insider Trading Alert - ANAC, N And PRAA Traded By Insiders

Stocks with insider trader activity include ANAC, N and PRAA

Anacor Pharmaceuticals Appoints Paul L. Berns As Chief Executive Officer

Anacor Pharmaceuticals Appoints Paul L. Berns As Chief Executive Officer

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the Company’s Board of Directors has appointed Paul L.

Anacor Pharmaceuticals Inc. Stock Upgraded (ANAC)

Anacor Pharmaceuticals Inc. Stock Upgraded (ANAC)

Anacor Pharmaceuticals (Nasdaq:ANAC) has been upgraded by TheStreet Ratings from a sell to buy.

Ratings Changes Today

Upgrades: ANAC, AUDC, AVHI, CATO, CUNB, DEG, DSCO, EVK, ORBC, OSUR, PHMD, QADA, QADB Downgrades: BXE, INTL Initiations: BFAM Read on to get TheStreet Quant Ratings' detailed report:

Anacor Pharmaceuticals Reports 2013 Fourth Quarter And Year-End Financial Results

Anacor Pharmaceuticals Reports 2013 Fourth Quarter And Year-End Financial Results

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2013.

Anacor Pharmaceuticals Announces Appointment Of Vince Ippolito As Chief Commercial Officer

Anacor Pharmaceuticals Announces Appointment Of Vince Ippolito As Chief Commercial Officer

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer.